Dr Martine Piccart speaks with ecancertv at AACR 2016 about the results of the MINDACT trial.
Using a new diagnostic assay, Mammaprint, to scan for a 70 gene signature, Dr Piccart reports significant predictive potential for determining breast cancer relapse risk.
With breast cancer being knowingly over-treated, the results from this trial enable the reduction of unnecessary treatments, even in patients classified as high risk via Adjuvant!Online, and lead to strategic de-escalation of chemotherapy.
This material may be protected by copyright law (Title 17 U.S. Code).
Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium